文献速递流行病学与生物统计

非肝实体器官移植受者已 resolved HBV 感染的 HBV 再激活发生率、危险因素与临床结局:系统综述与 Meta 分析

Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis.
PubMed 文献 · PLoS Med · 2023-03-15

该系统综述与 Meta 分析纳入 16 项回顾性队列研究、共 2913 例已 resolved HBV 感染的非肝实体器官移植受者,总体 HBV 再激活率为 2.5%(76/2913,95%CI 1.6%–3.6%,I²=55.0%)。抗-HBs 阴性、急性排斥史、ABO 血型不合移植、使用利妥昔单抗或抗胸腺细胞免疫球蛋白者再激活率更高。再激活者中 HBV 相关肝衰竭和 HBV 相关死亡均为 11.0%(7/52)。

要点

  • 已 resolved HBV 感染的非肝实体器官移植受者总体 HBV 再激活率为 2.5%(76/2913)。
  • 抗-HBs 阴性者再激活率 7.8%(34/421), crude OR 5.05(95%CI 2.83–9.00)。
  • 再激活者中 HBV 相关肝衰竭和 HBV 相关死亡均为 11.0%(7/52)。

核心结论

  • 已 resolved HBV 感染的非肝实体器官移植受者一旦发生 HBV 再激活,HBV 相关肝衰竭和 HBV 相关死亡风险高。
  • HBV 再激活的潜在危险因素包括使用利妥昔单抗、使用抗胸腺细胞免疫球蛋白、抗-HBs 阴性、急性排斥史和 ABO 血型不合移植。
  • 需要对 HBV 再激活高风险的非肝实体器官移植受者开展监测和常规抗病毒预防的进一步研究。

研究设计与样本

  • 系统综述与 Meta 分析,检索 PubMed、Embase 和 Cochrane Library 三个数据库至 2022 年 12 月 31 日。
  • 纳入报告非肝实体器官移植受者 HBV 再激活的临床研究,排除病例报告、病例系列和样本量小于 10 例的队列研究。
  • 共纳入 16 项回顾性队列研究、2913 例已 resolved HBV 感染的非肝实体器官移植受者。
  • 所有 Meta 分析采用随机效应模型。

主要发现

  • 总体 HBV 再激活率为 2.5%(76/2913;95%CI 1.6%–3.6%;I²=55.0%)。
  • 抗-HBs 阴性受者再激活率 7.8%(34/421;95%CI 5.2%–10.9%;I²=36.0%,汇总 6 项研究)。
  • 发生急性排斥者再激活率 5.8%(13/266;95%CI 2.3%–14.5%;I²=63.2%,汇总 3 项研究)。
  • 接受 ABO 血型不合移植者再激活率 7.0%(8/111;95%CI 2.9%–12.7%;I²=0%,汇总 3 项研究)。
  • 使用利妥昔单抗者再激活率 7.3%(10/133;95%CI 3.4%–12.6%;I²=0%,汇总 3 项研究);使用抗胸腺细胞免疫球蛋白者再激活率 4.9%(25/504;95%CI 2.5%–8.1%;I²=49.0%,汇总 4 项研究)。

关键数值与推荐

  • 抗-HBs 阴性 crude OR 5.05(95%CI 2.83–9.00;p<0.001;I²=0%)。
  • ABO 血型不合移植 crude OR 2.62(95%CI 1.05–6.04;p=0.040;I²=0%)。
  • 急性排斥史 crude OR 2.37(95%CI 1.13–4.97;p=0.022;I²=0%)。
  • 使用抗胸腺细胞免疫球蛋白 crude OR 3.19(95%CI 1.48–6.87;p=0.003;I²=0%)。
  • 使用利妥昔单抗 crude OR 3.16(95%CI 1.24–8.06;p=0.016;I²=0%);校正分析结果相似。

临床怎么用

  • 当前指南不推荐对已 resolved HBV 感染的非肝实体器官移植受者进行常规抗病毒预防,即使抗-HBs 阴性或接受强免疫抑制治疗。
  • 再激活者中 HBV 相关肝衰竭为 11.0%(7/52;95%CI 4.0%–20.8%;I²=0.3%),HBV 相关死亡为 11.0%(7/52;95%CI 4.0%–20.8%;I²=0.3%)。
  • 作者认为需要对 HBV 再激活高风险的非肝实体器官移植受者开展监测和常规抗病毒预防的进一步研究。

局限性

  • Meta 分析存在中等异质性。
  • 多数研究在肾移植受者中进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines do not recommend routine antiviral prophylaxis to prevent hepatitis B virus (HBV) reactivation in non-liver solid organ transplant (SOT) recipients with resolved HBV infection, even in anti-hepatitis B surface antigen (anti-HBs)-negative recipients and those receiving intense immunosuppression. This systematic review and meta-analysis aimed to determine the incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver SOT recipients. METHODS AND FINDINGS: Three databases (PubMed, Embase, and Cochrane Library) were systematically searched up to December 31, 2022. Clinical studies reporting HBV reactivation in non-liver SOT recipients were included. Case reports, case series, and cohort studies with a sample size of less than 10 patients were excluded. Random-effects analysis was used for all meta-analyses. We included 2,913 non-liver SOT recipients with resolved HBV infection from 16 retrospective cohort studies in the analysis. The overall HBV reactivation rate was 2.5% (76/2,913; 95% confidence interval [95% CI 1.6%, 3.6%]; I2 = 55.0%). Higher rates of reactivation were observed in recipients with negative anti-HBs (34/421; 7.8%; 95% CI [5.2%, 10.9%]; I2 = 36.0%) by pooling 6 studies, experiencing acute rejection (13/266; 5.8%; 95% CI [2.3%, 14.5%]; I2 = 63.2%) by pooling 3 studies, receiving ABO blood type-incompatible transplantation (8/111; 7.0%; 95% CI [2.9%, 12.7%]; I2 = 0%) by pooling 3 studies, receiving rituximab (10/133; 7.3%; 95% CI [3.4%, 12.6%]; I2 = 0%) by pooling 3 studies, and receiving anti-thymocyte immunoglobulin (ATG, 25/504; 4.9%; 95% CI [2.5%, 8.1%]; I2 = 49.0%) by pooling 4 studies. Among recipients with post-transplant HBV reactivation, 11.0% (7/52; 95% CI [4.0%, 20.8%]; I2 = 0.3%) developed HBV-related hepatic failure, and 11.0% (7/52; 95% CI [4.0%, 20.8%]; I2 = 0.3%) had HBV-related death. Negative anti-HBs (crude odds ratio [OR] 5.05; 95% CI [2.83, 9.00]; p < 0.001; I2 = 0%), ABO blood type-incompatible transplantation (crude OR 2.62; 95% CI [1.05, 6.04]; p = 0.040; I2 = 0%), history of acute rejection (crude OR 2.37; 95% CI [1.13, 4.97]; p = 0.022; I2 = 0%), ATG use (crude OR 3.19; 95% CI [1.48, 6.87]; p = 0.003; I2 = 0%), and rituximab use (crude OR 3.16; 95% CI [1.24, 8.06]; p = 0.016; I2 = 0%) increased the risk of reactivation. Adjusted analyses reported similar results. Limitations include moderate heterogeneity in the meta-analyses and that most studies were conducted in kidney transplant recipients. CONCLUSIONS: Non-liver SOT recipients with resolved HBV infection have a high risk of HBV-related hepatic failure and HBV-related death if HBV reactivation occurs. Potential risk factors for HBV reactivation include rituximab use, anti-thymocyte immunoglobulin use, anti-HBs negative status, acute rejection history, and ABO blood type-incompatible transplantation. Further research on monitoring and routine antiviral prophylaxis of non-liver SOT recipients at higher risk of HBV reactivation is required.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Yin S, Zhang F, Wu J, et al. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis. PLoS Med. 2023. PMID: 36920988. doi:10.1371/journal.pmed.1004196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。